Study was conducted in 20 patients with osteogen sarcoma of long tubular bones. Of 20 patients studied in 11 patients tumor was localized in femoral bone, in 6 patients in tibia and in 3 patients in fibula. Slices taken from the tumor in open biopsy were the object of research. Immune-hystochemical research was carried out by the standard technique applying antibodies to Bcl-2. The assessment response was made by visual simiquantity method: expression absence was-0, weak-1 (+), moderately expressed-2 (++), intensive-3 (+++). 17 patients were given chemoradiotherapy, 3 patients combined treatment (surgical + adjuvant chemotherapy). 12 got intraarterial chemotherapy (72 hours) by CAP regimen (Cyclophosphamide, Adriamycin, Cisplatin) – 4 cycles with three week interval. Then telegammatherapy, single dose 3.5 Gy up to general dose 60–70 Gy was made, later chemotherapy was completed up to 9 cycles at the same regimen. 8 patients were carried out 4 cycles of intra-arterial chemotherapy by MP regimen (Methotrexate, Cisplatin) with three week interval. Radiotherapy used subsequently (General dose 60–70 Gy) and chemotherapy was reached up to 9 cycles at the same regimen. Research has shown, that in the most of patients 13/20 (65 %) had moderately positive and low positive expression of Bcl-2 gene, in 4/20 (20 %) cases reaction was negative and in 3/20 (15 %) cases it was the expression of the given gene that was high. The assessment of treatment efficiency was carried out by WHO recommendation. The whole effect was obtained in 6 patients (30 %), partial in 11 (55 %) and progressing was in 3 (15 %). Most patients who were given the treatment by specific scheme: chemotherapy + radiotherapy + chemotherapy had good parameters in life expectancy, where 6 of 8 patients (75 %) lived without relapse and metastases more than one year. All patients (3) had numerous lung metastases in operation + chemotherapy group of patients. Aggressive current of tumoral process was characterized with high expression of Bcl-2 gene in tumor tissue. The level of expression Bcl-2 gene can testify the efficiency of conducted treatment.
